Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1434, Houston, TX, 77030, USA.
Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Breast Cancer Res Treat. 2019 Jul;176(2):435-444. doi: 10.1007/s10549-019-05243-7. Epub 2019 Apr 25.
The optimal management of breast cancer patients with a positive sentinel lymph node (SLN) who undergo mastectomy remains controversial. This study aimed to describe treatment patterns of patients with positive SLNs who undergo mastectomy using a large population-based database.
The NCDB was queried for cT1-2N0 breast cancer patients treated with mastectomy between 2006 and 2014 who had 1-2 positive SLNs. Patients receiving neoadjuvant chemotherapy were excluded. Axillary management included SLN dissection (SLND) alone, axillary lymph node dissection (ALND), post-mastectomy radiation (PMRT) alone, and ALND + PMRT. Trends of axillary management and patient characteristics were examined.
Among 12,190 patients who met study criteria, the use of ALND dropped with a corresponding increase in other approaches. In 2006, 34% of patients had SLND alone, 47% ALND, 8% PMRT and 11% ALND + PMRT. By 2014, 37% had SLND, 23% ALND, 27% PMRT and 13% ALND + PMRT. Patients who underwent SLND alone were older (mean 60.6 years) with more comorbidities (Charlson-Deyo score > 2), smaller primary tumors (mean 2.1 cm), well-differentiated histology, hormone receptor-positive, HER2-negative tumors, without lymphovascular invasion (all P values < 0.01). Treatment with SLND alone was more likely if patients had only one positive SLN (P < 0.001) or micrometastatic disease (P < 0.001), and were treated at community centers compared with academic centers (P < 0.001).
The management of breast cancer patients undergoing mastectomy with positive SLNs has evolved over time with decreased use of ALND and increased use of radiation. Some patient subsets are underrepresented in recent clinical trials, and therefore, future trials should focus on these patients.
对于接受乳房切除术且前哨淋巴结(SLN)阳性的乳腺癌患者,其最佳治疗方案仍存在争议。本研究旨在利用大型基于人群的数据库,描述 SLN 阳性并接受乳房切除术的患者的治疗模式。
从 2006 年至 2014 年期间,NCDB 中检索了接受乳房切除术且 SLN 为 1-2 个阳性的 cT1-2N0 乳腺癌患者,排除接受新辅助化疗的患者。腋窝管理包括 SLN 单独清扫术(SLND)、腋窝淋巴结清扫术(ALND)、乳房切除术后放疗(PMRT)单独和 ALND+PMRT。检查了腋窝管理和患者特征的趋势。
在符合研究标准的 12190 名患者中,ALND 的使用率下降,而其他方法的使用率相应增加。2006 年,34%的患者接受了 SLND 单独治疗,47%的患者接受了 ALND,8%的患者接受了 PMRT,11%的患者接受了 ALND+PMRT。到 2014 年,37%的患者接受了 SLND,23%的患者接受了 ALND,27%的患者接受了 PMRT,13%的患者接受了 ALND+PMRT。接受 SLND 单独治疗的患者年龄较大(平均 60.6 岁),合并症较多(Charlson-Deyo 评分>2),原发肿瘤较小(平均 2.1cm),组织学分化较好,激素受体阳性,HER2 阴性,无淋巴管血管侵犯(所有 P 值均<0.01)。如果患者仅存在一个阳性 SLN(P<0.001)或微转移疾病(P<0.001),且在社区中心而非学术中心接受治疗(P<0.001),则更有可能接受 SLND 单独治疗。
随着 ALND 使用率的降低和放疗使用率的增加,SLN 阳性接受乳房切除术的乳腺癌患者的治疗方式已经发生了演变。一些患者亚组在最近的临床试验中代表性不足,因此,未来的试验应集中在这些患者上。